We focus on innovative therapeutic approaches targeting specific tumour-host interactions, hypoxia, radio- or immunotherapy resistance. We will develop more effective CAR-T cell therapy targeting tumour specific. As many of pHGGs are epigenetically driven tumour we will evaluate epigenetic inhibitors activated specifically in the tumour microenvironment to reduce toxicity and enhance responses to radio- and immunotherapy. Brain is separated from the body by a blood-brain barrier, a network of blood vessels and tissue, made up of closely sticking cells which helps keep harmful substances from reaching the brain. But it create the obstacle to anti-tumour drugs limiting their effectiveness. We will produce nanocarriers for targeted drug delivery to the brain to augment their action and limit whole body toxicity.